Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Malignant thymoma; Thymoma
- Focus Adverse reactions
- 07 Sep 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 07 Sep 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2024.
- 11 Nov 2022 Planned number of patients changed from 30 to 37.